Yale Medicine School: Newly Designed Molecule Is Promising Potential Therapy for Deadly Lung Condition
October 28, 2022
October 28, 2022
NEW HAVEN, Connecticut, Oct. 28 (TNSjou) -- Yale School of Medicine issued the following news on Oct. 27, 2022:
Idiopathic pulmonary fibrosis (IPF) is a deadly condition. The only available therapies can slow disease progression, but they are not a cure and often cause intolerable side effects. Patients diagnosed with the disease will die within three to five years of diagnosis. "It is more lethal than most cancers," says Naftali Kaminski, MD, Boehringer Ingelheim Pharmace . . .
Idiopathic pulmonary fibrosis (IPF) is a deadly condition. The only available therapies can slow disease progression, but they are not a cure and often cause intolerable side effects. Patients diagnosed with the disease will die within three to five years of diagnosis. "It is more lethal than most cancers," says Naftali Kaminski, MD, Boehringer Ingelheim Pharmace . . .